Free cash flow remains consistently negative, with quarterly outflows peaking at $53.0 million in 2025Q2, highlighting a structural inability to fund operations without external capital.
| Cash from Operations | -97.43M | -59.55M | -59.66M | -49.64M | -22.42M | -12.7M | -7.58M |
| Operating CF Margin % | -1363.65% | -229.19% | -244.98% | -326.24% | -2002.05% | -87.11% | -1012.56% |
| Operating CF Growth % | -63.62% | 0.19% | -20.19% | -121.38% | -76.55% | -67.47% | - |
| Net Income | -20.6M | -63.69M | -65.77M | -60.51M | -110.09M | -3.48M | -12.26M |
| Depreciation & Amortization | 79K | 193K | 169K | 159K | 105K | 9K | 5.98K |
| Stock-Based Compensation | 9.87M | 10.84M | 11.95M | 9.64M | 2.11M | 139K | 106.14K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -88.72M | -10.61M | -2.75M | 6.11M | 81.5M | 2.21M | 3.43M |
| Working Capital Changes | 1.93M | 3.72M | -3.27M | -5.04M | 3.96M | -11.59M | 1.12M |
| Change in Receivables | -1M | -415K | -3.63M | -1.86M | 14.15M | -13.86M | -39.7K |
| Change in Inventory | 170K | 1.12M | -3.27M | -1.86M | 0 | 0 | 0 |
| Change in Payables | 3.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 11.89M | 25.2M | 83.21M | -132.89M | 25.15M | 0 | -35.71K |
| Capital Expenditures | -552K | -1.65M | -3.97M | -444K | -46K | 0 | -35.71K |
| CapEx % of Revenue | 7.73% | 6.37% | 16.31% | 2.92% | 4.11% | - | 4.77% |
| Acquisitions | 101.29M | 0 | 0 | 0 | 25.2M | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 94.38M | 130K | 326K | 72.62M | 141.8M | 1.19M | 8.07M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 1.19M | 8.07M |
| Equity Issued (Net) | 100M | 130K | 0 | 72.5M | 155M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -4.41M | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -5.63M | -16K | 326K | 120K | -8.78M | 0 | 0 |
| Net Change in Cash | 8.9M | -34.22M | 23.87M | -109.91M | 144.53M | -11.51M | 15.96M |
| Free Cash Flow | -97.98M | -61.2M | -63.63M | -50.08M | -22.47M | -12.7M | -7.62M |
| FCF Margin % | -1371.38% | -235.55% | -261.29% | -329.15% | -2006.16% | -87.11% | -1017.33% |
| FCF Growth % | -60.1% | 3.82% | -27.06% | -122.9% | -76.91% | -66.68% | - |
| FCF per Share | -1.58 | -2.26 | -2.36 | -2.22 | -2.52 | -0.72 | -0.95 |
| FCF Conversion (FCF/Net Income) | 4.73x | 0.93x | 0.91x | 0.82x | 0.20x | 3.65x | 0.62x |
| Interest Paid | 0 | 211K | 230K | 230K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent clinical funding shortfall
According to quarterly cash flow statements, the relationship between net income and operating cash flow is highly erratic, with the OCF/NI ratio fluctuating from -0.16 in 2025Q1 to 1.25 in 2024Q3, suggesting that GAAP earnings provide little insight into the company's actual cash-basis burn rate.
The extreme variance in the OCF/NI ratio indicates that non-cash items and accounting adjustments frequently distort the bottom line, rendering net income a poor proxy for operational health. Investors should focus exclusively on the net cash used in operating activities, as the disconnect between reported earnings and cash outflows suggests that the company's financial position is more precarious than GAAP figures might imply.
As reported in financial statements, Whitehawk Therapeutics consistently records negative free cash flow, with quarterly outflows reaching as high as $53 million in 2025Q2, highlighting a structural inability to generate self-sustaining cash flows while the company remains in a pre-commercial, high-burn clinical development phase.
The trajectory of free cash flow remains deeply negative, with no evidence of a narrowing gap between cash inflows and outflows. This persistent deficit suggests that the company is entirely dependent on external capital markets to fund its R&D pipeline, leaving it highly susceptible to shifts in investor sentiment toward the biotechnology sector.
Based on the provided cash flow data, working capital changes have been highly inconsistent, swinging from a $4.5 million inflow in 2025Q4 to a $3.4 million outflow in 2025Q2, which may indicate erratic timing of milestone-related payments or irregular management of accounts payable and accrued liabilities.
The lack of a predictable working capital cycle suggests that the company's cash management is reactive rather than strategic. Such volatility in working capital often reflects the lumpy nature of clinical-stage biotech operations, where cash flows are dictated by the timing of trial-related expenses rather than a steady-state business model.
Data from recent filings indicates that stock-based compensation remains a significant non-cash add-back, consistently ranging between $1.7 million and $3.6 million per quarter, which effectively masks the true economic cost of talent retention and dilutes the impact of the company's ongoing cash depletion.
While stock-based compensation is a standard practice in the industry, its persistence at these levels suggests that the company is relying on equity to preserve cash, which may lead to significant shareholder dilution over time. Analysts should treat these figures as a real economic cost, as the reliance on equity-based incentives may be necessary to retain specialized personnel in the absence of a viable commercial product.
Quick answers to the most common questions about buying WHWK stock.
Whitehawk Therapeutics Inc (WHWK) generated $-97.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Whitehawk Therapeutics Inc (WHWK) reported negative free cash flow of $98.0M in 2025, indicating capital requirements exceeded cash from operations.
Whitehawk Therapeutics Inc (WHWK) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.